Roche (RHHBY) hopes to go toe-to-toe with Eli Lilly (LLY) and Novo Nordisk (NVO) in the red-hot weight-loss space. The Swiss drug giant said Thursday it expects to seek approval for four new obesity drugs in 2028. “Every patient is on an individual weight-loss journey,” Teresa Graham, chief executive of Roche’s pharma division, said during the earnings conference call, according…
